A Practical Regulatory Timeline for First-in-Human Medical Device Studies in Latin America (2026)

For MedTech founders and regulatory directors, Latin America can be the fastest path to a first-in-human (FIH) medical device milestone—if you treat timeline as an operational deliverable, not a hope. The region is not a single market: documentation, ethics review cadence, import steps, and contract mechanics vary by country and by whether your study is observational, non-significant risk (NSR), or significant risk.

This article provides a practical way to plan an FIH device study timeline across Latin America in 2026: what workstreams to run in parallel, where delays typically occur, and how to de-risk your critical path without compromising compliance or participant safety.

1) Start with a “workstream map,” not a single Gantt chart

FIH device studies commonly stall because sponsors build one linear plan when the reality is a set of interdependent workstreams. A useful planning framework separates your launch into seven workstreams, each with its own owners, documents, and review cycles:

• Protocol package (protocol, IB/IFU, risk analysis, monitoring plan, DSMB plan if needed)
• Country regulatory submission (device classification/route, authority forms, translations, legalization requirements if any)
• Ethics approval (central/local IRB/ethics committee workflow, consent language, recruitment materials)
• Site contracting & budgets (CTA, indemnification, insurance certificates, payment triggers)
• Import & logistics (shipping lanes, customs broker readiness, temp-control, labeling)
• Site activation (SIV readiness, staff training, device accountability tools)
• First patient in (FPI) (screening plan, recruitment levers, backup sites)

When these workstreams are run deliberately in parallel, many sponsors can compress timelines materially versus the “submit, wait, then do the next thing” approach.

2) A realistic 2026 timeline template (what to do in each month)

Every program differs, but for early-feasibility or FIH device studies, a practical timeline template often looks like this:

• Weeks 0–2: Feasibility + site shortlist. Confirm patient pool, investigator interest, imaging/lab capabilities, and whether your endpoints are standard-of-care in that setting.
• Weeks 1–4: Submission-ready document set. Build the “country-ready” version of the protocol package: consistent terminology, device description aligned with IFU, and localized consent templates.
• Weeks 3–8: Parallel ethics + regulatory preparation. Prepare authority-specific forms while the ethics packet is being finalized; do not wait for final contracts to start regulatory readiness.
• Weeks 6–12: Contracts, budgets, and insurance. In many countries, the slow step is not scientific review but the negotiation of indemnification clauses, invoice rules, and insurance wording.
• Weeks 8–14: Import and first shipment readiness. Align labeling, airway bills, and broker processes early; confirm whether your device is shipped as commercial goods, samples, or study materials and plan accordingly.
• Weeks 12–18: SIV + site activation. Execute training, device accountability procedures, and data capture dry runs.
• Weeks 16–24: FPI window. A strong screening plan and backup sites protect you from “approval achieved, recruitment delayed.”

Rather than treating “approval” as the finish line, treat it as the midpoint: you still need operational readiness to reach FPI.

3) Where timelines slip (and how to protect the critical path)

Across Latin America, recurring delays tend to cluster into a few categories:

• Translation and document consistency issues. Inconsistencies between protocol, IFU, and consent language trigger rework during ethics review.
• Contract sequencing mistakes. If you wait for final CTA language before starting budget alignment or insurance certificates, you create avoidable idle time.
• Import readiness left too late. Even when the device is low-risk, shipments can be rejected if labeling, documentation, or declared values are unclear.
• Over-reliance on a single site. A single high-performing hospital is not a recruitment strategy; build a backup shortlist early.

Two simple practices prevent many timeline slips: (1) run a weekly “document control” check to keep all versions synchronized, and (2) hold a pre-import readiness call with your broker and study team before any shipment is booked.

4) Country selection: choose based on constraints, not hype

Latin America offers multiple attractive options, but the best country for your FIH study depends on constraints:

• Need speed? Prioritize clear ethics pathways, experienced investigators, and predictable import lanes for study materials.
• Need specific patient phenotypes? Choose where that patient population is concentrated and where endpoints align with standard clinical practice.
• Need imaging or specialized procedures? Ensure site infrastructure and maintenance/QA standards can support your device and endpoints.

A practical rule: pick the country where your operational bottleneck is easiest to solve. If your bottleneck is import complexity, choose the market where your logistics and broker experience is strongest. If your bottleneck is investigator capability, choose the market with the deepest specialty network.

FAQ

• How long does an FIH device study typically take to reach first patient in (FPI) in Latin America?
  Many sponsors plan a 4–6 month window from kick-off to FPI when workstreams run in parallel, but timelines depend on device risk, required reviews, contracting speed, and import readiness.
• What is the most common avoidable delay?
  Contracting and insurance language misalignment, followed closely by late import readiness and inconsistent translated documents.
• How can sponsors reduce timeline risk without cutting corners?
  Use a workstream map, keep document versions synchronized, and build redundancy (backup sites, backup shipping lanes, and a recruitment contingency plan).

Bottom line: In 2026, sponsors that treat Latin America FIH timelines as an integrated regulatory-and-operations program—rather than a single “submission” event—can reach FPI faster and with fewer surprises.